A Randomized Phase II trial of Adjuvant Chemotherapy with S-1 vs S-1 and Gemcitabine(GS) vs Gemcitabine alone(GEM) in Patients with resected Pancreatic Cancer (CAP-002 study)
Abstract No: 4056
Presenter: Hideyuki Yoshitomi, MD
研究设计
GEM组：GEM 1000mg/m2, d1,8,15，q4w×12S-1组：S-1 80/100/120mg/d, d1-14，q3w×16GS组：S-1 60/80/100mg/d, d1-14，GEM 1000mg/m2, d8,15，q3w×16
随机、开放、多中心II期研究
胰腺癌术后患者
随机分层：JPS分期I-III期 vs IVa+b期，R0 vs R1，中心
A组GEM
B组S-1
C组GEM/S-1(GS)
主要终点：2年DFS次要终点：OS，安全性，可行性
Hideyuki Yoshitomi ,et  ...